Study finds the missing link behind long COVID fatigue and brain fog
A new brain imaging study led by researchers at Canada’s Centre for Addiction and Mental Health (CAMH) offers some of the strongest evidence yet that long COVID damages dopamine-releasing neurons in the brain. Published in eBioMedicine, the study suggests that this damage to the brain's dopamine system is a key driver behind persistent, debilitating symptoms like fatigue, brain fog , loss of motivation, memory problems, and slower physical movement.
A hidden crisis without clear answers
Long COVID currently affects roughly 5% of the global population, including about two million people in Canada. Despite how widespread the condition is, doctors have struggled to offer effective treatments because the underlying biological causes remain poorly understood.
Mapping the brain's dopamine networks
To look inside the brain, the CAMH team used Positron Emission Tomography (PET) scans to measure a specific biomarker that reflects the health and density of dopamine nerve terminals. They compared people living with long COVID against healthy control subjects. The scans revealed significantly lower levels of this dopamine marker across the entire striatum, which is the brain region responsible for movement, motivation, and complex thinking.
Linking specific symptoms to brain damage
The researchers discovered that specific patterns of dopamine loss directly matched specific patient symptoms:
Ventral striatum damage correlated with a major loss of motivation.
Dorsal putamen damage linked directly to slower physical movement.
Caudate putamen damage matched up with memory difficulties.
"Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons," says Dr. Jeffrey Meyer, senior author of the study. He notes that this type of neural injury is already known to cause motor slowing and motivation loss in other neurological conditions.
Connection between inflammation and neural injury
This milestone study builds directly on earlier work from the same team, which showed that long COVID patients suffer from unusually high brain inflammation. That inflammation was particularly intense in regions packed with dopamine-releasing neurons. Together, the two studies paint a clear picture: persistent brain inflammation appears to actively injure dopamine neurons, directly triggering long COVID's core neurological symptoms.
Roadmap for medical treatments
Up to this point, most long COVID research focused on general immune dysfunction and inflammation, with very few clinical trials addressing dopamine pathways. These findings open up a clear new direction for treatment. Dr. Meyer suggests that existing medications designed to boost dopamine activity, such as dopamine precursors or drugs that prevent dopamine breakdown, could potentially be repurposed to treat long COVID.
Real biological validation for patients
For patients, the findings provide long-awaited medical validation. Susan Deuville, a lived-experience research advisor on the project who contracted COVID in 2021, shared that the research brings hope and confirms that long COVID is a very real, biologically measurable condition.
Clinical trials
The researchers are now moving fast. In collaboration with the University Health Network (UHN) and supported by the Canadian Institutes of Health Research (CIHR), the team plans to launch a clinical trial targeting dopamine function to see if these treatments can restore memory, motivation, and energy levels.
A hidden crisis without clear answers
Long COVID currently affects roughly 5% of the global population, including about two million people in Canada. Despite how widespread the condition is, doctors have struggled to offer effective treatments because the underlying biological causes remain poorly understood.
Mapping the brain's dopamine networks
To look inside the brain, the CAMH team used Positron Emission Tomography (PET) scans to measure a specific biomarker that reflects the health and density of dopamine nerve terminals. They compared people living with long COVID against healthy control subjects. The scans revealed significantly lower levels of this dopamine marker across the entire striatum, which is the brain region responsible for movement, motivation, and complex thinking.
Linking specific symptoms to brain damage
The researchers discovered that specific patterns of dopamine loss directly matched specific patient symptoms:
Ventral striatum damage correlated with a major loss of motivation.
Dorsal putamen damage linked directly to slower physical movement.
Caudate putamen damage matched up with memory difficulties.
"Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons," says Dr. Jeffrey Meyer, senior author of the study. He notes that this type of neural injury is already known to cause motor slowing and motivation loss in other neurological conditions.
Connection between inflammation and neural injury
This milestone study builds directly on earlier work from the same team, which showed that long COVID patients suffer from unusually high brain inflammation. That inflammation was particularly intense in regions packed with dopamine-releasing neurons. Together, the two studies paint a clear picture: persistent brain inflammation appears to actively injure dopamine neurons, directly triggering long COVID's core neurological symptoms.
Roadmap for medical treatments
Up to this point, most long COVID research focused on general immune dysfunction and inflammation, with very few clinical trials addressing dopamine pathways. These findings open up a clear new direction for treatment. Dr. Meyer suggests that existing medications designed to boost dopamine activity, such as dopamine precursors or drugs that prevent dopamine breakdown, could potentially be repurposed to treat long COVID.
Real biological validation for patients
For patients, the findings provide long-awaited medical validation. Susan Deuville, a lived-experience research advisor on the project who contracted COVID in 2021, shared that the research brings hope and confirms that long COVID is a very real, biologically measurable condition.
Clinical trials
The researchers are now moving fast. In collaboration with the University Health Network (UHN) and supported by the Canadian Institutes of Health Research (CIHR), the team plans to launch a clinical trial targeting dopamine function to see if these treatments can restore memory, motivation, and energy levels.
Next Story